Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Other ICR Research
  • View item
  • Home
  • ICR Divisions
  • Other ICR Research
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

The methyl-CpG- binding protein MECP2 is required for prostate cancer cell growth

Thumbnail
Date
2006-03-02
ICR Author
Hudson, David
Author
Bernard, D
Gil, J
Dumont, P
Rizzo, S
Monte, D
Quatannens, B
Hudson, D
Visakorpi, T
Fuks, F
de Launoit, Y
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
The incidence of prostate cancer is increasing in western countries because of population aging. Prostate cancer begins as an androgen-dependent disease, but it can become androgen independent at a later stage or in tumors recurring after an antihormonal treatment. Although many genetic events have been described to be involved in androgen-dependent and/or -independent prostate cancer growth, little is known about the contribution of epigenetic events. Here we have examined the possibility that the methyl-CpG-binding protein MECP2 might play a role in controlling the growth of prostate cancer cells. Inhibition of MECP2 expression by stable short hairpin RNA stopped the growth of both normal and cancer human prostate cells. In addition, ectopic expression of the MECP2 conferred a growth advantage to human prostate cancer cells. More importantly, this expression allowed androgen-dependent cells to grow independently of androgen stimulation and to retain tumorigenic properties in androgen-depleted conditions. Analysis of signaling pathways showed that this effect is independent of androgen receptor signaling. Instead, MECP2 appears to act by maintaining a constant c-myc level during antihormonal treatment. We further show that MECP2-expressing cells possess a functional p53 pathway and are still responsive to chemotherapeutic drugs.
URI
https://repository.icr.ac.uk/handle/internal/2547
DOI
https://doi.org/10.1038/sj.onc.1209179
Collections
  • Other ICR Research
Language
eng
License start date
2006-03-02
Citation
ONCOGENE, 2006, 25 pp. 1358 - 1366
Publisher
NATURE PUBLISHING GROUP

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.